References
- L Gordon. Woman's Body, Woman's Right: birth control in America. 1990; Penguin: Harmondsworth.
- Social Exclusion Unit. Teenage pregnancy. 1999; HMSO: London.
- Department of Health. Better prevention, Better services, Better sexual health: the national strategy for sexual health and HIV. 2001; HMSO: London.
- National Institute for Health and Clinical Excellence. Long-acting reversible contraception: the effective and appropriate use of long-acting reversible contraception. CG30. 2005; NICE: London. http://guidance.nice.org.uk/CG30
- I Mavranezouli. The cost effectiveness of long-acting reversible contraceptive methods in the UK: analysis based on the decision-analytic model developed for the National Institute for Health and Clinical Excellence (NICE) clinical practice guideline. Human Reproduction. 23(6): 2008; 1338–1345.
- PD Blumenthal, A Voedisch, K Gemzell-Danielsson. Strategies to prevent unintended pregnancy: increasing use of long-acting reversible contraception. Human Reproduction. 17(1): 2010; 121–137.
- Department of Health. A Framework for Sexual Health Improvement in England. March 2013. https://www.wp.dh.gov.uk/publications/files/2013/03/9287-2900714-TSO-SexualHealthPolicyNW_ACCESSIBLE.pdf
- A Smith, S Reuter. An assessment of the use of Implanon in three community services. Journal of Family Planning and Reproductive Health Care. 28(4): 2002; 193–196.
- F Lakha, AF Glasier. Continuation rates of Implanon in the UK: data from an observational study in a clinical setting. Contraception. 74: 2006; 287–289.
- PD Blumenthal, K Gemzell-Danielsson, M Marintcheva-Petrova. Tolerability and clinical safety of Implanon. European Journal of Contraception and Reproductive Health Care. 13(Suppl.I): 2008; 29–36.
- Z Harel, FM Biro, LM Kollar. Adolescents' reasons for and experience after discontinuation of the long-acting contraceptives Depo-Provera and Norplant. Journal of Adolescent Health. 19: 1996; 118–123.
- K Rai, S Gupta, S Cotter. Experience with Implanon in a north east London family planning clinic. European Journal of Contraception and Reproductive Health Care. 9: 2004; 39–46.
- H Sangi-Haghpeykar, M Frank, L Leonard. A qualitative study of perceptions, attitudes, and experiences of long-term levonorgestrel implant users. Women & Health. 30(4): 2000; 93–108.
- E Cheung, C Free. Factors influencing young women's decision making regarding hormonal contraceptives: a qualitative study. Contraception. 71: 2005; 426–431.
- H Kuiper, S Miller, E Martinez. Urban adolescent females' views on the implant and contraceptive decision-making: a double paradox. Family Planning Perspectives. 29(4): 1997; 167–172.
- S Walker. Mechanistic and “natural” body metaphors and their effects on attitudes to hormonal contraception. Women & Health. 52(8): 2012; 788–803.
- J Butler. Bodies that matter. 1993; Routledge: London.
- M Shildrick. Leaky Bodies and Boundaries: Feminism, Postmodernism and (Bio) ethics. 1997; Routledge: London.
- SK Laws. Issues of Blood. The Politics of Menstruation. 1990; Macmillan: Basingstoke.
- V Braun, V Clarke. Using thematic analysis in psychology. Qualitative Research in Psychology. 3: 2006; 77–101.
- Hoggart L, Newton VL, Dickson J. Understanding Long-acting Reversible Contraception: an in-depth investigation into sub-dermal contraceptive implant removal amongst teenagers in London. A report for the London Sexual Health Commissioning Programme, 2013.
- VL Newton. Status passage, stigma and menstrual management: ‘starting’ and ‘being on’. Social Theory and Health. 10(4): 2012; 392–407.
- M Hyttel, JJK Rasanathan, M Tellier. Use of injectable hormonal contraceptives: diverging perspectives of women and men, service providers and policymakers in Uganda. Reproductive Health Matters. 20(40): 2012; 148–157.
- FDA-Approved Patient Labeling: Implanon®. http://www.merck.com/product/usa/pi_circulars/i/implanon/implanon_ppi.pdf.